Ï㽶ÊÓƵ

Sachin Apte
( out of 28 reviews )

Sachin Apte, MD, MBA, MS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Gynecology and Mammography
Salt Lake City
801-213-4269

  • Sachin Apte, MD, MS, MBA is Chief Clinical Officer at Huntsman Cancer Institute and Physician-in-Chief of the cancer hospital, part of the Ï㽶ÊÓƵ of Utah Health system. Apte is a board-certified gynecologic oncologist and a professor of obstetrics and gynecology at Ï㽶ÊÓƵ of Utah Health. He previously served as chair of the department of gynecologic oncology and then as associate chief medical officer at Moffitt Cancer Center.

    He is committed to performance excellence by striving for high quality, innovative cancer care delivery that is fully integrated into the research mission, with a focus on value and sustainability for our patients, health system, and the communities we serve. His research program focuses on clinical trials for new investigational therapies in patients with gynecologic cancers, as well as improving surgical quality and outcomes.

    He obtained his bachelor of science in chemical engineering from Cornell Ï㽶ÊÓƵ and his medical degree from The Ohio State Ï㽶ÊÓƵ. He then completed a fellowship in gynecologic oncology at M. D. Anderson Cancer Center while also obtaining his masters of science in cancer biology from the Ï㽶ÊÓƵ of Texas Health Science Center at Houston. Apte obtained an MBA from the Ï㽶ÊÓƵ of Tennessee in 2012. Apte joined Huntsman Cancer Institute in 2021.

    Specialties

    Board Certification

    American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
    American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

    Patient Rating

    5.0 /5
    ( out of 28 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 18, 2024
    HUNTSMAN CANCER CENTER

    He so Caring and listens to you. I'm so glad he's Doctor

    May 10, 2024
    HUNTSMAN CANCER CENTER

    Very intense knowledge and extremely professional. Both he and his staff are friendly and great communicators.

    April 26, 2024
    HUNTSMAN CANCER CENTER

    Very professional

    April 12, 2024
    HUNTSMAN CANCER CENTER

    He is so caring and really talks to you and explains everything so you understand it.

    April 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Apte is very easy to talk to and very respectful to me as well as my husband and daughter who were with me. I have every confidentance in his knowledge and concern with my ongoing care plan.

    February 10, 2024
    HUNTSMAN CANCER CENTER

    I will recommend Dr Sachin he is a great doctor

    January 15, 2024
    HUNTSMAN CANCER CENTER

    Very understandable, patient and easy to talk to.

    May 19, 2023
    HUNTSMAN CANCER CENTER

    He was so very professional and caring.

    May 13, 2023
    HUNTSMAN CANCER CENTER

    He is a wonderful, caring Doctor who make me feel safe.

    See More Patient Comments

  • Sachin Apte, MD, MS, MBA is Chief Clinical Officer at Huntsman Cancer Institute and Physician-in-Chief of the cancer hospital, part of the Ï㽶ÊÓƵ of Utah Health system. Apte is a board-certified gynecologic oncologist and a professor of obstetrics and gynecology at Ï㽶ÊÓƵ of Utah Health. He previously served as chair of the department of gynecologic oncology and then as associate chief medical officer at Moffitt Cancer Center.

    He is committed to performance excellence by striving for high quality, innovative cancer care delivery that is fully integrated into the research mission, with a focus on value and sustainability for our patients, health system, and the communities we serve. His research program focuses on clinical trials for new investigational therapies in patients with gynecologic cancers, as well as improving surgical quality and outcomes.

    He obtained his bachelor of science in chemical engineering from Cornell Ï㽶ÊÓƵ and his medical degree from The Ohio State Ï㽶ÊÓƵ. He then completed a fellowship in gynecologic oncology at M. D. Anderson Cancer Center while also obtaining his masters of science in cancer biology from the Ï㽶ÊÓƵ of Texas Health Science Center at Houston. Apte obtained an MBA from the Ï㽶ÊÓƵ of Tennessee in 2012. Apte joined Huntsman Cancer Institute in 2021.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Primary
    Academic Divisions Gynecological Oncology
    Board Certification
    American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
    American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

    Education history

    Graduate Training Business - Ï㽶ÊÓƵ of Tennessee M.B.A.
    Fellowship Gynecologic Oncology - Ï㽶ÊÓƵ of Texas M.D. Anderson Cancer Center Fellow
    Graduate Training Cancer Biology - Ï㽶ÊÓƵ of Texas, Health Science Center at Houston M.S.
    Internship/Residency Obstetrics & Gynecology - Ohio State Ï㽶ÊÓƵ College of Medicine Intern/Resident
    Professional Medical Medicine - Ohio State Ï㽶ÊÓƵ College of Medicine M.D.
    Undergraduate Chemical Engineering - Cornell Ï㽶ÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Kuznicki M, Mallen A, McClung EC, Robertson SE, Todd S, Boulware D, Martin S, Quilitz R, Vargas RJ, Apte SM (2020). Dual antibiotic prevention bundle is associated with decreased surgical site infections. Int J Gynecol Cancer, 30(9), 1411-1417. ()
    2. Liang MI, Aviki EM, Wright JD, Havrilesky LJ, Boyd LR, Moss HA, Jewell EL, Cohn DE, Apte SM, Timmins PF 3rd, Alvarez RD, Rathbun J, Lipinski E, White S, Siverio-Minardi D, Ko EM (2020). Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. Gynecol Oncol, 156(3), 701-709. ()
    3. Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME (2019). High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecol Oncol, 156(2), 349-356. ()
    4. Hoffman MS, Xiong Y, Apte S, Roberts W, Wenham RM (2019). Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice. Gynecol Oncol, 155(2), 359-364. ()
    5. Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, Chon HS, Small BJ, Gonzalez BD, Jim HSL (2018). A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol, 152(2), 310-315. ()
    6. Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS (2018). Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol, 218(4), 436.e1-436.e7. ()
    7. Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM (2017). Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer, 17(1), 407. ()
    8. Apte SM (2017). An oncologist's perspective: preparation for new payment models in cancer care. Am J Manag Care, 23(5 Spec No.), SP169-SP172. ()
    9. Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM (2016). Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Int J Gynecol Cancer, 26(3), 553-60. ()
    10. Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM (2016). Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol, 4(3), 399-404. ()
    11. Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM (2015). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol, 140(2), 259-63. ()
    12. Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet J (2015). Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Oncol Lett, 11(1), 323-329. ()
    13. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL, National Comprehensive Cancer Network (2015). Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw, 13(11), 1321-31. ()
    14. Bush SH, Apte SM (2015). Robotic-Assisted Surgery in Gynecological Oncology. Cancer Control, 22(3), 307-13. ()
    15. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR 3rd, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL (2015). Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw, 13(4), 395-404. ()
    16. Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM (2015). BAD-mediated apoptotic pathway is associated with human cancer development. Int J Mol Med, 35(4), 1081-7. ()
    17. Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte SM (2015). Metastatic VIPoma presenting as an ovarian mass. Int J Surg Case Rep, 17, 167-9. ()
    18. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR 3rd, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M (2014). Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw, 12(2), 248-80. ()
    19. Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM (2013). Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep, 31(1), 376-83. ()
    20. Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM (2013). Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol, 209(6), 576.e1-576.e16. ()
    21. Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM (2013). Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecol Oncol, 131(1), 207-12. ()
    22. Phillips KM, Faul LA, Small BJ, Jacobsen PB, Apte SM, Jim HS (2012). Comparing the retrospective reports of fatigue using the Fatigue Symptom Index with daily diary ratings in women receiving chemotherapy for gynecologic cancer. J Pain Symptom Manage, 46(2), 282-8. ()
    23. Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA (2013). A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol, 130(1), 19-24. ()
    24. Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM (2013). Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol, 208(6), 501.e1-7. ()
    25. Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM (2013). A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep, 29(5), 2011-8. ()
    26. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M, National Comprehensive Cancer Network (2013). Cervical cancer. J Natl Compr Canc Netw, 11(3), 320-43. ()
    27. Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM (2012). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol, 41(1), 179-88. ()
    28. Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM (2012). Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer, 22(6), 960-7. ()
    29. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer, 106(12), 1967-75. ()
    30. Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM (2011). The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol, 124(1), 119-24. ()
    31. Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM (2012). BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol, 23(1), 35-42. ()
    32. Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB (2011). Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Ann Behav Med, 42(3), 321-33. ()
    33. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM (2011). BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res, 17(19), 6356-66. ()
    34. Ramirez I, Chon HS, Apte SM (2011). The role of surgery in the management of epithelial ovarian cancer. Cancer Control, 18(1), 22-30. ()
    35. Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR 3rd, Martin L, Morgan MA, Morgan RJ Jr, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Valea FA, National Comprehensive Cancer Networks (2010). Cervical cancer. J Natl Compr Canc Netw, 8(12), 1388-416. ()
    36. Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (2010). Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol, 203(2), 158.e1-40. ()
    37. Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM (2009). Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer, 19(9), 1564-9. ()
    38. Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM (2009). Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol, 100(6), 511-4. ()
    39. Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS (2008). Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol, 201(1), 116.e1-3. ()
    40. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM (2009). MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol, 113(2), 249-55. ()
    41. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS (2009). A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol, 113(2), 210-5. ()
    42. Humphrey MM, Apte SM (2008). The use of minimally invasive surgery for endometrial cancer. Cancer Control, 16(1), 30-7. ()
    43. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster JM (2008). MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol, 110(2), 206-15. ()
    44. Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS (2006). Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med, 4, 16. ()
    45. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ (2003). Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol, 93(1), 78-86. ()
    46. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ (2002). Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res, 8(7), 2413-22. ()
    47. Vaccarello L, Apte SM, Copeland LJ, Boutselis JG, Rubin SC (1999). Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. Gynecol Oncol, 74(1), 118-22. ()
    48. Bumgardner GL, Li J, Apte S, Heininger M, Frankel WL (1998). Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology, 28(2), 466-74. ()
    49. Vaccarello L, Apte SM, Diaz PT, Lewandowski GS, Copeland LJ (1997). Respiratory failure from metastatic choriocarcinoma: a survivor of mechanical ventilation. Gynecol Oncol, 67(1), 111-4. ()
    50. Hammer DA, Tempelman LA, Apte SM (1993). Statistics of cell adhesion under hydrodynamic flow: simulation and experiment. Blood Cells, 19(2), 261-75; discussion 275-7. ()
    51. Hammer DA, Apte SM (1992). Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys J, 63(1), 35-57. ()

    Case Report

    1. Wells AE, Mallen AM, Bui MM, Reed DR, Apte SM (2019). NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report. Gynecol Oncol Rep, 28, 141-144. ()

  • News & Podcasts

    News

    Huntsman Cancer Institute News